FDA-cleared profile

SugarBug (1.x)

Bench7, Inc. · X-ray/Radiography · FDA-cleared (510(k))

Authorized purpose: Provides automated concurrent-read detection and segmentation of caries on bitewing radiographs in patients 18 and older, adding information for the dentist while requiring complete dentist review and judgment.

Clinical role
Concurrent-read computer-assisted detection software that segments suspected caries on bitewing radiographs, labeling features the reader should examine for evidence of decay; it does not replace a complete dentist's review or clinical judgment.
Images and patients
X-ray/Radiography · Dental/Maxillofacial
Key limitation
Keep in mind: The device is not a replacement for dentist review or judgment; the FDA routine-use description of local processing does not establish every current commercial host, export, or enterprise deployment configuration.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Provides automated concurrent-read detection and segmentation of caries on bitewing radiographs in patients 18 and older, adding information for the dentist while requiring complete dentist review and judgment.
  • Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Dental/Maxillofacial Input: Bitewing radiographs of patients 18 years and older, taken in as screen captures rather than image file input; the device can process images of 300 pixel resolution.
  • Who uses it?Intended users: Dentists
  • What does the software produce?Output: The AI model performs semantic segmentation on bitewing radiographs, assigning a probability value to each pixel for the possibility that it contains decay. A threshold is applied to determine which pixels are labeled in the output. The device outputs labeled regions indicating areas suspected of caries (decay) to aid the dentist in diagnosis.
  • What is its most important limitation?Key limitation: The device is not a replacement for dentist review or judgment; the FDA routine-use description of local processing does not establish every current commercial host, export, or enterprise deployment configuration.

Clinical takeaway. Clinical role: Provides automated concurrent-read detection and segmentation of caries on bitewing radiographs in patients 18 and older, adding information for the dentist while requiring complete dentist review and judgment.

Evidence takeaway. Evidence from the reviewed source record: Study type: Both. Cases: 400. Reported sensitivity: 68.6% (95% CI: 65.5%, 71.7%). Reader-study cases: 300. Readers: 12. Reader-study sensitivity: 67.4% (95% CI: 61.5%, 72.8%)

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Provides automated concurrent-read detection and segmentation of caries on bitewing radiographs in patients 18 and older, adding information for the dentist while requiring complete dentist review and judgment.
  • Exact FDA submission
  • Checked 2026-09-06

Exact clinical-use normalization from the FDA packet; this text is also the locked corrections value.

Workflow role
Concurrent-read computer-assisted detection software that segments suspected caries on bitewing radiographs, labeling features the reader should examine for evidence of decay; it does not replace a complete dentist's review or clinical judgment.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "SugarBug is a radiological, automated, concurrent read, computer-assisted detection software intended to aid in the detection and segmentation of caries on bitewing radiographs." … "uses machine learning to label features that the reader should examine for evidence of decay.". Read from the exact FDA decision document on 2026-11-14.

Required input
Bitewing radiographs of patients 18 years and older, taken in as screen captures rather than image file input; the device can process images of 300 pixel resolution.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "caries on bitewing radiographs. The device provides additional information for the dentist to use in their diagnosis of a tooth surface suspected of being carious. Sugarbug is intended to be used on patients 18 years and older." … "Sugarbug processes screen captures as opposed to image file input". Read from the exact FDA decision document on 2026-11-14.

Output and clinician action
The AI model performs semantic segmentation on bitewing radiographs, assigning a probability value to each pixel for the possibility that it contains decay. A threshold is applied to determine which pixels are labeled in the output. The device outputs labeled regions indicating areas suspected of caries (decay) to aid the dentist in diagnosis.
  • Exact FDA submission
  • Checked 2026-09-01

Clinical output reported in the exact-submission ACR model card.

Care setting
Adult
  • Exact FDA submission
  • Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Intended users
Dentists
  • Exact FDA submission
  • Checked 2026-09-01

Intended-user text reported in the exact-submission ACR model card.

Limitations
The device is not a replacement for dentist review or judgment; the FDA routine-use description of local processing does not establish every current commercial host, export, or enterprise deployment configuration.
  • Exact FDA submission
  • Checked 2026-09-06

Exact-product limitations and clinician-review boundary from the FDA packet.

Evidence summary
Study type: Both. Cases: 400. Reported sensitivity: 68.6% (95% CI: 65.5%, 71.7%). Reader-study cases: 300. Readers: 12. Reader-study sensitivity: 67.4% (95% CI: 61.5%, 72.8%)
  • Exact FDA submission
  • Checked 2026-09-01

Structured study metadata from the exact-submission ACR model card; this is not an independent evidence synthesis.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Study type: Both. Cases: 400. Reported sensitivity: 68.6% (95% CI: 65.5%, 71.7%). Reader-study cases: 300. Readers: 12. Reader-study sensitivity: 67.4% (95% CI: 61.5%, 72.8%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Structured study metadata from the exact-submission ACR model card; this is not an independent evidence synthesis.

Reported sensitivity
68.6% (95% CI: 65.5%, 71.7%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Lesion-level sensitivity

0.686 proportion

  • EndpointLesion-level caries sensitivity
  • PopulationStandalone evaluation of 400 deidentified bitewing radiographs containing 481 caries lesions
  • Tested versionSugarBug 1.x; FDA submission K250264

SugarBug (1.x) regulatory performance study summary

  • DesignStand-alone performance and reader study (ACR AI Central category)
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K250264
  • Samplen=400
  • IndependenceIndependence not established

K250264

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Pricing is recorded, but no exact-product procurement price with a stated offer scope is published in the reviewed sources.

Public pricing
$99/month per office; the official page says unlimited AI analysis on up to five computers and offline use after activation on supported Windows systems. This is the Sugarbot Detect family offer; exact commercial mapping to FDA SugarBug (1.x) requires confirmation.
  • Product family
  • Checked 2026-09-07

Narrative vendor offer retained without normalizing the dollar symbol into a structured currency field.

Reimbursement

Reimbursement
CMS states that Original Medicare does not pay for care, treatment, filling, removal or replacement of teeth or the structures directly supporting them (Social Security Act 1862(a)(12), 42 CFR 411.15(i)), except for inpatient hospital services and dental services that are integral to certain Medicare-covered medical services. This product's FDA-cleared use is analysis of dental radiographs, which falls in routine dental care, so no separate Medicare payment is expected outside those exceptions. Dental plan, CDT coding and private payer treatment of AI radiograph analysis were not reviewed, and no price or payment amount was established.
  • Service-level, not product-specific
  • Checked 2026-10-25

No product-specific code

Original Medicare dental-service exclusion applies to routine dental care; dental plan and private payer treatment not reviewed

Medicare (Original Medicare, CMS) · United States

Service-level exclusion from the CMS dental coverage page; it does not address this product by name and does not establish coverage or payment by dental plans or other payers.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Bitewing radiographs of patients 18 years and older, taken in as screen captures rather than image file input; the device can process images of 300 pixel resolution.

    Scope: Exact FDA submission. Packet wording: "caries on bitewing radiographs. The device provides additional information for the dentist to use in their diagnosis of a tooth surface suspected of being carious. Sugarbug is intended to be used on patients 18 years and older." … "Sugarbug processes screen captures as opposed to image file input". Read from the exact FDA decision document on 2026-11-14.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-11-14 · FDA 510(k) decision material K250264: SugarBug (1.x)

  2. Routing

    Source context, not route validation: The exact FDA package describes SugarBug processing screen captures as opposed to image file input, reading the selected image with local processing; images are not imported or sent to a cloud server during routine use. Interface versions and local compatibility require confirmation.

    Scope: Exact FDA submission. Packet wording: "Different processing input - Sugarbug processes screen captures as opposed to image file input" … "The software reads the selected image using local processing; images are not imported or sent to a cloud server any time during routine use.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-11-14 · FDA 510(k) decision material K250264: SugarBug (1.x)

  3. AI processing

    Source context, not route validation: Local processing during routine use; the FDA summary states that images are not imported or sent to a cloud server.

    Scope: Exact FDA submission. Exact FDA packet routine-use processing description; current enterprise host configuration still requires confirmation.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-06 · FDA 510(k) decision material K250264: SugarBug (1.x)

  4. Returned objects

    Source context, not route validation: The AI model performs semantic segmentation on bitewing radiographs, assigning a probability value to each pixel for the possibility that it contains decay. A threshold is applied to determine which pixels are labeled in the output. The device outputs labeled regions indicating areas suspected of caries (decay) to aid the dentist in diagnosis.

    Scope: Exact FDA submission. Clinical output reported in the exact-submission ACR model card.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-01 · SugarBug (1.x) model card (K250264)

  5. Viewer/worklist/report

    Unresolved route: The AI model performs semantic segmentation on bitewing radiographs, assigning a probability value to each pixel for the possibility that it contains decay. A threshold is applied to determine which pixels are labeled in the output. The device outputs labeled regions indicating areas suspected of caries (decay) to aid the dentist in diagnosis.

    Scope: Exact FDA submission. Clinical output reported in the exact-submission ACR model card.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-01 · SugarBug (1.x) model card (K250264)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Local processing during routine use; the FDA summary states that images are not imported or sent to a cloud server.
  • Exact FDA submission
  • Checked 2026-09-06

Exact FDA packet routine-use processing description; current enterprise host configuration still requires confirmation.

Integration
The exact FDA package describes SugarBug processing screen captures as opposed to image file input, reading the selected image with local processing; images are not imported or sent to a cloud server during routine use. Interface versions and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Different processing input - Sugarbug processes screen captures as opposed to image file input" … "The software reads the selected image using local processing; images are not imported or sent to a cloud server any time during routine use.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Family desktop workflow

The vendor says Sugarbot Detect runs on the desktop, works with existing imaging software without an integration, and can be installed in less than 15 minutes.

product family · checked 2026-09-07

Vendor product page; verify exact commercial mapping to SugarBug (1.x).

Family local processing claim

The vendor says images are processed on-device without cloud upload or an internet connection during the advertised workflow.

product family · checked 2026-09-07

Vendor claim only; security, retention, and enterprise controls were not established.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K250264
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
X-ray/Radiography
  • Public source
  • Exact FDA submission
  • Checked 2026-09-06

Imaging modality reported in the exact-submission ACR AI Central model card.

Anatomy
Dental/Maxillofacial
  • Public source
  • Exact FDA submission
  • Checked 2026-09-06

Anatomy normalized from explicit exact-submission ACR model-card wording.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-11-07
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
27Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored exact-submission candidate metadata had zero PubMed and ClinicalTrials.gov identifiers; this metadata screening is not a full paper or registry-record review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, vendor pricing observation, literature index, trial registry, payer policy, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-08-13 - Exact FDA submission

    FDA authorization does not establish the current commercial security posture. Request data-flow diagrams, hosting and retention details, access controls, audit logging, attestations, and incident-response documentation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-08-13 - Exact FDA submission

    Training, onboarding, competency, and support commitments are commercial implementation details that require current vendor documentation.

  • Monitoring: Not verified - checked 2026-08-13 - Exact FDA submission

    Local acceptance testing, production monitoring, drift review, update control, and incident escalation require a current vendor and site-specific governance plan.

10 sources - 3 history items

Source ledger

  1. K250264 FDA decision source

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, purpose, modality, anatomy

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. SugarBug (1.x) model card (K250264)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: purpose, modality, intendedUsers, careSetting, output, reportedSensitivity, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. FDA 510(k) decision material K250264: SugarBug (1.x)

    U.S. Food and Drug Administration - Accessed 2026-09-06

    Scope: identity, clinical, evidence, implementation, integration

  8. Sugarbot Detect product page

    Bench7 / Sugarbot AI - Accessed 2026-09-07

    Scope: buyer_workflow, implementation, clinical

  9. Get Sugarbot Detect

    Bench7 / Sugarbot AI - Accessed 2026-09-07

    Scope: pricing, implementation

  10. Medicare Dental Coverage (CMS provider page)

    Centers for Medicare & Medicaid Services - Accessed 2026-10-25

    Scope: reimbursement, payerPolicy

Research history

  1. K250264 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K243234

Second Opinion® CS

Pearl Inc.

Authorized purpose: Acts as a CADe second reader to detect and segment caries on periapical radiographs of permanent teeth in patients aged 12 years and older; clinicians review the contours and percentage analysis in context.

Modality
X-ray/Radiography
Anatomy
Dental/Maxillofacial
Decision
2025-06-12
FDA-cleared K242437

Smile Dx®

Cube Click, Inc.

Authorized purpose: Aids dentists reviewing bitewing and periapical radiographs of permanent teeth by detecting/segmenting caries and periapical radiolucencies, identifying restorations and dental anatomy, and measuring mesial/distal bone levels; it does not replace dentist review.

Modality
X-ray/Radiography
Anatomy
Dental/Maxillofacial
Decision
2025-05-14
FDA-cleared K252086

DTX Studio Assist

Nobel Biocare C/O Medicim NV

Authorized purpose: Analyzes two-dimensional bitewing and periapical radiographs of permanent teeth in patients aged 15 and older to identify and localize caries, calculus, periapical radiolucency, root canal filling deficiency, discrepancy at an existing restoration margin, and bone loss; also supports alveolar bone-level measurement and restoration/dental-anatomy segmentation as an adjunct to dentist review.

Modality
X-ray/Radiography
Anatomy
Dental/Maxillofacial
Decision
2025-11-17
FDA-cleared K250753

VELMENI for DENTISTS (V4D)

Velmeni Inc.

Authorized purpose: Assists dentists in detecting caries, fillings/restorations, fixed prostheses, and implants on digital bitewing, periapical, and panoramic radiographs of permanent teeth in patients aged 15 years and older; final diagnoses and treatment plans remain the dentist's responsibility.

Modality
X-ray/Radiography
Anatomy
Dental/Maxillofacial
Decision
2025-09-02

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history